Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older

NCT04505722 is registered in ClinicalTrials.gov with Janssen Vaccines & Prevention B.V. as lead sponsor.

NCT NCT04505722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04505722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older
Lead sponsor
Janssen Vaccines & Prevention B.V.
Phase
Phase 3
Overall status
Completed
Start date
September 7, 2020
Completion date
March 31, 2023
Enrollment
44,325 (actual)
Sites
225

Conditions

As the registry lists them; a condition with its own page is linked.

participants with or without stable co-morbidities associated with progression to severe covid-19 at different stages of the protocol